MRGPRX2 Mediates Mast Cell Activation and Neurogenic Inflammation in Lesional Biopsies from Patients with Atopic Dermatitis

Zachary Benet¹, Alan Wong¹, Julia Schanin¹, Melina Butuci¹, Bhupinder Singh¹, and Bradford A. Youngblood¹

¹Allakos Inc., San Carlos, CA



EAACI 2022 July 1st Abstract #000880




• Lirentelimab is an investigational drug candidate and is not FDA/EMA approved

• This study was funded by Allakos Inc.




Mast Cells Drive Itch and Neurogenic Inflammation in Skin



- Mast cells are elevated in atopic dermatitis (AD) tissue and are poised to be key drivers of itch
- Crosstalk between mast cells and sensory neurons contribute to itch via MRGPRX2
- The role of MRGPRX2 in contributing to AD pathogenesis has not been well studied




Evaluation of Local Inflammation in Fresh Skin Biopsies via Ex Vivo Immunological Assays






AD Skin Lesions Display Mixed Inflammatory Profile




AD skin biopsies show evidence of both Th1 and Th2 inflammation

Mast Cells and Eosinophils are Elevated in AD Lesions




MRGPRX2-Substance P Axis is Active in AD Lesional Skin



MRGPRX2-mediated MC activation is found in AD skin



Substance P-mediated MC Activation Induces MRGPRX2 Internalization




EAACI HYBRID CONGRESS 2022 SOURCE: Allakos Data on File.

Sialic Acid-binding Immunoglobulin-like Lectin (Siglec)-8 is an Inhibitory Cell Surface Receptor on Mast Cells


Siglec-8

- Siglec-8 is a cell surface receptor of the CD33-related subfamily of Siglecs only found in humans
- Selectively expressed on eosinophils and mast cells
- Upon antibody engagement, Siglec-8 induces eosinophil depletion and mast cell inhibition



SOURCE: Adapted from O'Reilly and Paulson. Siglecs as targets for therapy in immune-cell-mediated disease. *Trends in Pharmacological Sciences.* Vol.30 No.5. 2009.

Siglec-8 mAb Inhibits Substance P-mediated Activation of MCs



Siglec-8 represents a novel target to inhibit MRGPRX2-mediated MC activation

Summary

- Mast cells are elevated and activated in lesional skin of patients with AD
- Activation is in part driven through the MRGPRX2 axis
 - Levels of substance P are elevated in biopsy supernatants
 - MRGPRX2 surface levels are reduced on mast cells in lesional skin
- MRGPRX2 is internalized upon ligand engagement
- Targeting the inhibitory receptor Siglec-8 on mast cells represents an attractive approach to reduce MRGPRX2-mediated MC activation

